Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 1/20 | 0.44 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 10/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 10/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | NQO2 | P16083 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3709099 | 1.00 | QPCT (0.44) | QPCTQPCTLMTNR1AMTNR1BHTT | |
| SCHEMBL31457424 | 0.78 | GLB1 (0.42) | HTTSMN1; SMN2 | |
| SCHEMBL15463276 | 0.76 | HDAC1 (0.37) | QPCTQPCTLMTNR1AMTNR1BKDM4E | |
| SCHEMBL31457421 | 0.76 | GLB1 (0.38) | HTTSMN1; SMN2 | |
| SCHEMBL13801487 | 0.73 | MAPT (0.37) | HTTSMN1; SMN2 | |
| SCHEMBL3696353 | 0.72 | QPCT (0.55) | QPCTQPCTLMTNR1AMTNR1BHTT | |
| SCHEMBL553085 | 0.68 | KDM4E (0.70) | KDM4ESMN1; SMN2HSD17B10 | |
| SCHEMBL166146 | 0.68 | ACACB (0.54) | QPCTQPCTLMTNR1AMTNR1BKDM4E | |
| SCHEMBL13840691 | 0.67 | NQO2 (0.41) | MTNR1AMTNR1BNQO2 | |
| SCHEMBL15526231 | 0.64 | MTNR1A (0.50) | MTNR1AMTNR1BKDM4ESMN1; SMN2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140038968-A1 | AMINO-HETEROARYL-CONTAINING PROKINETICIN 1 RECEPTOR ANTAGONISTS | COATS STEVEN J (US) | 2014-02-06 | — | — | US | disclosed |
| US-8324380-B2 | Amino-heteroaryl-containing prokineticin 1 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2012-12-04 | — | — | US | disclosed |
| EP-2215067-A1 | AMINO-HETEROARYL-CONTAINING PROKINETICIN 1 RECEPTOR ANTAGONISTS | Janssen Pharmaceutica, N.V. (BE) | 2010-08-11 | — | — | EP | disclosed |
| US-20090163505-A1 | AMINO-HETEROARYL-CONTAINING PROKINETICIN 1 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2009-06-25 | — | — | US | disclosed |
| WO-2009058653-A1 | AMINO-HETEROARYL-CONTAINING PROKINETICIN 1 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140038968-A1 | AMINO-HETEROARYL-CONTAINING PROKINETICIN 1 RECEPTOR ANTAGONISTS | PROKR1, PROKR2, GIPR | QPCT 487/4885QPCTL 535/4885MTNR1A 45/4885 |
| US-20090163505-A1 | AMINO-HETEROARYL-CONTAINING PROKINETICIN 1 RECEPTOR ANTAGONISTS | PROKR1, PROKR2, GIPR | QPCT 487/4885QPCTL 535/4885MTNR1A 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.